Cited by 623Pancreatic function and diabetesDiabetes and associated disordersDiabetes, Cardiovascular Risks, and Lipoproteins

The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes

Open access
Wilkin, T. J.·2001·Diabetologia

Abstract

Blood glucose concentrations are controlled by a loop incorporating two components, the beta cells which secrete insulin and the insulin-sensitive tissues (liver, muscle, adipose) which respond to it. Loss of blood glucose control might result from failure of the beta cells to secrete insulin, resistance of the tissues to its action, or a combination of both. The distinctions between Type I (insulin-dependent) and Type II (non-insulin-dependent) diabetes mellitus are becoming increasingly blurred both clinically and aetiologically, where beta-cell insufficiency is the shared characteristic. The 'Accelerator Hypothesis' identifies three processes which variably accelerate the loss of beta cells through apoptosis: constitution, insulin resistance and autoimmunity. None of the accelerators leads to diabetes without excess weight gain, a trend which the 'Accelerator Hypothesis' deems central to the rising incidence of both types of diabetes in the industrially developed world. Weight gain causes an increase in insulin resistance, which results in the weakening of glucose control. The rising blood glucose (glucotoxicity) accelerates beta-cell apoptosis directly in all and, by inducing beta-cell immunogens, further accelerates it in a subset genetically predisposed to autoimmunity. Rather than overlap between two types of diabetes, the 'Accelerator Hypothesis' envisages overlay. Body mass is central to the development and rising incidence of all diabetes. Only tempo distinguishes the 'types'. The control of weight gain, and with it insulin resistance, could be the means of minimising both.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s001250100548

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. UK Prospective Diabetes Study Group (1995) UK pro- spective study 16. Overview of six years' therapy of Type II diabetes. Diabetes 44: 1249±1258 41. Yu l, Eisenbarth GS (1998) Immunology of Type I diabetes and related endocrine disorders.In: Klibanski A, Biller BMK (eds) Clinical endocrinology update. The Endocrine Society Press, Bethesda pp258±266

Cited by

Sorted by citations

Authors
Wilkin, T. J.
Affiliations
Derriford Hospital (GB)
Corresponding author
Wilkin, T. J.
Venue
Diabetologia
Published
2001-07-01
Volume
44
Issue
7
Pages
914-922
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W1966671518
Cited by
623
References
38
Citations by year
2026: 14 · 2025: 13 · 2024: 20 · 2023: 20 · 2022: 27 · 2021: 24 · 2020: 18 · 2019: 21 · 2018: 19 · 2017: 20 · 2016: 22 · 2015: 20 · 2014: 31 · 2013: 30 · 2012: 26
FWCI
3.65
Type
journal article
Language
en
Open access
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 1 diabetes, type 2 diabetes, beta-cell apoptosis, weight gain, insulin resistance, glucotoxicity, autoimmunity, body mass, diabetes incidence
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Models, Biological, Phagocytosis, Risk Factors, Weight Gain, Prevalence, Apoptosis, Developed Countries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review